Tuesday, October 8, 2024
9:34 AM EST – BioVaxys Technology Corp : Announces it has engaged Rajkannan Rajagopalan, PhD, as Advisor for development and production of the Company’s DPX™ formulations.
Dr. Rajagopalan has a PhD in Pharmaceutical Chemistry/Physical Chemistry, with over 20 years of experience in nanoparticles formulation development for biomolecules (peptides, proteins, nucleic acids, VLPs, mAbs) delivery to treat cancer, infectious diseases and autoimmune disorders. Most recently, Dr. Rajagopalan was Senior Director of Formulation Development at IMV, Inc., where he developed DPX-based vaccines to treat breast, ovarian, bladder and hard to reach cancers; and DPX-based RSV, Anthrax, ZIKA, Ebola, Tuberculosis and SARS infectious disease vaccines, as well as VLP-encapsulated DPX vaccines to treat Malaria and RSV infections. BioVaxys Technology Corp (C.BIOV) shares were unchanged at 0.04.
Stocks in Play: BioVaxys Technology Corp, Tue, 08 Oct 2024 09:42:06 EST